49140 Clinical similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results
Feldman, Steven, Narbutt, Joanna, Girolomoni, Giampiero, Brzezicki, Jan, Reznichenko, Nataliya, Pulka, Grazyna, Dmowska-Stecewicz, Magdalena, Lee, Jiyoon, Lee, Minkyung, Rho, Young Hee
Published in Journal of the American Academy of Dermatology (01.09.2024)
Published in Journal of the American Academy of Dermatology (01.09.2024)
Get full text
Journal Article
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis
Feldman, Steven R., Narbutt, Joanna, Girolomoni, Giampiero, Brzezicki, Jan, Reznichenko, Nataliya, Zegadło-Mylik, Maria Agnieszka, Pulka, Grazyna, Dmowska-Stecewicz, Magdalena, Kłujszo, Elżbieta, Rekalov, Dmytro, Rajzer, Lidia, Lee, Jiyoon, Lee, Minkyung, Rho, Young Hee
Published in Journal of the American Academy of Dermatology (01.09.2024)
Published in Journal of the American Academy of Dermatology (01.09.2024)
Get full text
Journal Article